Ask AI
ProCE Banner Activity

Advances in Smoldering and Transplant-Eligible Newly Diagnosed Multiple Myeloma: Risk Stratification, MRD-Guided Therapy, and Emerging Treatment Strategies

Slideset

Download this slideset to explore contemporary risk stratification and treatment strategies for smoldering and transplant-eligible newly diagnosed multiple myeloma, including MRD-guided care, quadruplet induction regimens, transplant considerations, and emerging immunotherapy approaches.

Released: July 31, 2026

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by educational grants from Johnson & Johnson and Sanofi Genzyme.

Johnson & Johnson

Sanofi Genzyme

Target Audience

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with high-risk smoldering or newly diagnosed multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recommend individualized treatment strategies leveraging anti-CD38–based quadruplets for appropriate patients with newly diagnosed symptomatic MM based on the latest clinical evidence, expert recommendations, and patient/disease factors

  • Educate patients with high-risk smoldering MM on the latest evidence and expert guidance on anti-CD38–based treatment to support informed shared decision-making